Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Down 98.8% in January

Vincerx Pharma, Inc. (NASDAQ:VINC) was the recipient of a significant decrease in short interest during the month of January. As of January 15th, there was short interest totalling 55,700 shares, a decrease of 98.8% from the December 31st total of 4,710,000 shares. Based on an average daily trading volume, of 7,300,000 shares, the short-interest ratio is currently 0.0 days.

Institutional Trading of Vincerx Pharma

A hedge fund recently raised its stake in Vincerx Pharma stock. Marshall Wace LLP boosted its position in shares of Vincerx Pharma, Inc. (NASDAQ:VINC) by 359.1% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 328,533 shares of the company’s stock after purchasing an additional 256,967 shares during the quarter. Marshall Wace LLP owned about 1.11% of Vincerx Pharma worth $266,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 44.02% of the company’s stock.

Vincerx Pharma Trading Down 3.8 %

Shares of VINC stock traded down $0.06 during trading hours on Thursday, hitting $1.50. 985,186 shares of the company’s stock were exchanged, compared to its average volume of 1,223,157. The business’s 50 day simple moving average is $4.01 and its 200-day simple moving average is $8.84. Vincerx Pharma has a 12-month low of $1.40 and a 12-month high of $187.44. The company has a market capitalization of $2.52 million, a PE ratio of -1.46 and a beta of 1.48.

Analyst Upgrades and Downgrades

Separately, Leerink Partners cut their price objective on Vincerx Pharma from $80.00 to $40.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.